MREO logo

Mereo BioPharma (MREO)

Profile

Full Name

Mereo BioPharma Group plc

Ticker Symbol

MREO

Exchange

NASDAQ

Country

United Kingdom

IPO

April 24, 2019

Indexes

Not included

Employees

36

Key Details

Price

$2.33(-8.63%)

Market cap

$370.47M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

-

Annual EPS

-$0.30(-50.00% YoY)

PE ratio

-

Next earnings date

May 15, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Apr 9, 25 Needham
Buy
Mar 27, 25 JP Morgan
Overweight
Mar 26, 25 Needham
Buy
Mar 18, 25 Cantor Fitzgerald
Overweight
Jan 13, 25 Needham
Buy
Dec 24, 24 LifeSci Capital
Outperform
Dec 17, 24 Needham
Buy
Dec 6, 24 Jefferies
Buy
Nov 12, 24 Needham
Buy
Oct 1, 24 Cantor Fitzgerald
Overweight

Institutional Ownership

  • What is the ticker symbol for Mereo BioPharma?
  • Does Mereo BioPharma pay dividends?
  • What sector is Mereo BioPharma in?
  • What industry is Mereo BioPharma in?
  • What country is Mereo BioPharma based in?
  • When did Mereo BioPharma go public?
  • Is Mereo BioPharma in the S&P 500?
  • Is Mereo BioPharma in the NASDAQ 100?
  • Is Mereo BioPharma in the Dow Jones?
  • When was Mereo BioPharma's last earnings report?
  • When does Mereo BioPharma report earnings?
  • Should I buy Mereo BioPharma stock now?

What is the ticker symbol for Mereo BioPharma?

The ticker symbol for Mereo BioPharma is NASDAQ:MREO

Does Mereo BioPharma pay dividends?

No, Mereo BioPharma does not pay dividends

What sector is Mereo BioPharma in?

Mereo BioPharma is in the Healthcare sector

What industry is Mereo BioPharma in?

Mereo BioPharma is in the Biotechnology industry

What country is Mereo BioPharma based in?

Mereo BioPharma is headquartered in United Kingdom

When did Mereo BioPharma go public?

Mereo BioPharma's initial public offering (IPO) was on April 24, 2019

Is Mereo BioPharma in the S&P 500?

No, Mereo BioPharma is not included in the S&P 500 index

Is Mereo BioPharma in the NASDAQ 100?

No, Mereo BioPharma is not included in the NASDAQ 100 index

Is Mereo BioPharma in the Dow Jones?

No, Mereo BioPharma is not included in the Dow Jones index

When was Mereo BioPharma's last earnings report?

Mereo BioPharma's most recent earnings report was on Mar 26, 2025

When does Mereo BioPharma report earnings?

The next expected earnings date for Mereo BioPharma is May 15, 2025

Should I buy Mereo BioPharma stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page